GalleonBio has developed a novel topical treatment, GB400
GB100 is the first in a series of products specifically designed to both prevent and treat radiodermatitis in head and neck cancer patients requiring pain reduction combined with antipruritic activity. GB100 has been assessed in FDA approved phase Ia and a Ib studies and its phase II study will be completed in 2021 for the prevention and treatment of radiodermatitis in head and neck cancer. As pruritis is yet to be address by existing topicals GB100 was designed specifically to reduce pain and to break the itch-scratch inflammatory cycle.
GalleonBio has developed GB400, with unique chemistry and additional mechanisms of action. GB400 is a first in class bio-topical product for the management of mild to moderate psoriasis and other dermatological conditions. GB400 biomarker and animal data, as well as data from other research formulations and from its individual constituents, indicate potent anti-inflammatory, immunomodulatory, and antipruritic activity. GB400 is a patented combination of three known chemical entities displaying anti oxidative, anti-inflammatory and immunomodulatory activity. Individual therapeutic use of these components is supported by published clinical data and real-life experience, demonstrating an excellent safety profile. A proof of concept plaque patch test study is pending in psoriasis to be completed by the end of 2021.
GB200 and GB300 are also conjugate products specifically designed to address acute pain in peripheral neuropathy associated with diabetes and chemotherapy. This is an area of huge unmet need that requires a novel topical therapy that will alleviate patients pain and itch. These two products are based on in house conjugated formulations aiming to deliver synergistic anti-inflammatory, antioxidant, and immunomodulatory effects, initially in the management of neuropathic pain (NP) and in other dermatological and peripheral pain diseases.
GB600 is GalleonBio’s latest conjugate product designed to advance efficacy in new indications.
| Code | Form | Main Indication | Formulation | Pre Clinical | Phase I | Phase II |
|---|---|---|---|---|---|---|
| GB100 | Topical | Radiodermatitis | ||||
| GB100 | Topical | Chemotherapy Induced Neuropathy | ||||
| GB400 | Topical | Psoriasis | ||||
| GB300 | Topical | Diabetic Neuropathy | ||||
| GB600 | Topical | Atopic Dermatitis |